Comparison of two different iron oxide-based contrast agents for discrimination of benign and malignant lymph nodes

Investigative Radiology

Volumn 47, Issue 9, 2012, Pages 511-515

  Kinner, Sonja ^a   Maderwald, Stefan ^a,b   Albert, Juliane ^a   Parohl, Nina ^a   Corot, Claire ^c   Robert, Philippe ^c   Baba, Hideo A ^a   Barkhausen, Jörg ^d  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b ERWIN L HAHN INSTITUTE FOR MAGNETIC RESONANCE IMAGING   (Germany)

^c Laboratoire Guerbet   (France)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

contrast agents; lymphography; magnetic resonance imaging; ultrasmall particles of iron oxide (USPIO)

Indexed keywords

P 904; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; LYMPH NODE; LYMPHOGRAPHY; LYMPHOMA; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; RABBIT; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO;

EID: 84864867003     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3182587744     Document Type: Article

References (30)

1. Yoshimura G, Sakurai T, Oura S, et al. Evaluation of axillary lymph node status in breast cancer with MRI. Breast Cancer. 1999;6:249-258.
2. Kimura K, Tanigawa N, Matsuki M, et al. High-resolution MR lymphography using ultrasmall superparamagnetic iron oxide (USPIO) in the evaluation of axillary lymph nodes in patients with early stage breast cancer: preliminary results. Breast Cancer. 2009;17:241-246.
3. Scheidler J, Hricak H, Yu KK, et al. Radiological evaluation of lymph node metastases in patients withcervical cancer.Ameta-analysis. JAMA. 1997;278:1096-1101.
4. Kim SH, Kim SC, Choi BI, et al. Uterine cervical carcinoma: evaluation of pelvic lymph node metastasis withMRimaging. Radiology. 1994;190:807-811.
5. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-nodemetastases in prostate cancer.NEnglJMed. 2003;348:2491-2499.
6. Tsuda N, Tsuji T, Kato N. Interstitial magnetic resonance lymphography using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid in rabbits with lymph node metastasis. Invest Radiol. 2005;40:306-312.
7. Eiber M, Beer AJ, Holzapfel K, et al. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MRimaging. Invest Radiol. 2010;45:15-23. doi:10.1097/RLI. 0b013e3181bbdc2f.
8. Wu L, Cao Y, Liao C, et al. Diagnostic performance of USPIO-enhanced MRI for lymph-node metastases in different body regions: a meta-analysis. Eur J Radiol. 2011;80:582-589.
9. Corot CPM, Guilbert I. Superparamagnetic contrast agents. In: Modo MJBJ, ed. Molecular and Cellular MR Imaging. Boca Raton, FL: CRC; 2007:59-83.
10. Kinner S, Maderwald S, Parohl N, et al. Contrast-enhanced magnetic resonance angiography in rabbits: evaluation of the gadolinium-based agent P846 and the iron-based blood pool agent P904 in comparison with gadoterate meglumine. Invest Radiol. 2011;46:524-529. doi:10.1097/RLI.0b013e31821ae21f.
11. Sigovan M, Bessaad A, Alsaid H, et al. Assessment of age modulated vascular inflammation in ApoE-/-mice by USPIO-enhanced magnetic resonance imaging. Invest Radiol. 2010;45:702-707. doi:10.1097/RLI.0b013e3181f16e5a.
12. Wagner S. Benign lymph node hyperplasia and lymph node metastases in rabbits. Animal models for magnetic resonance lymphography. Invest Radiol. 1994;29:364-371.
13. Dunne AA, Kuropkat C, Sapundzhiev N, et al. Intravenous chemotherapy with cisplatin for regional lymph node metastases of auricular VX2 carcinoma. Anticancer Res. 2004;24:1785-1790.
14. Bennett B, Check IJ, Olsen MR, et al. A comparison of commercially available adjuvants for use in research. J Immunol Methods. 1992;153:31-40.
15. Stewart-Tull DES. The Use of Adjuvants in Experimental Vaccines: II.Water-in-Oil Emulsions: Freund's Complete and lncomplete Adjuvants. Methods Mol Med. Humana Press; 1996;4:141-145.
16. McClure SJ, Wagland BM, Emery DL. Effects of Freund's adjuvants on local, draining and circulating lymphocyte populations in sheep. Immunol Cell Biol. 1991;69:361-367.
17. Bernd H, De Kerviler E, Gaillard S, et al. Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program. Invest Radiol. 2009;44:336-342. doi:10.1097/RLI.0b013e3181a0068b.
18. Koh DM, George C, Temple L, et al. Diagnostic accuracy of nodal enhancement pattern of rectal cancer at MRI enhanced with ultrasmall superparamagnetic iron oxide: findings in pathologically matched mesorectal lymph nodes. AJR Am J Roentgenol. 2009;194:W505YW513.
19. Hövels AM, Heesakkers RAM, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387-395.
20. Sigovan M, Boussel L, Sulaiman A, et al. Rapid-clearance iron nanoparticles for inflammation imaging of atherosclerotic plaque: initial experience in animal model. Radiology. 2009;252:401-409.
21. Bellin MF, Roy C, Kinkel K, et al. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particlesVinitial clinical experience. Radiology. 1998;207:799-808.
22. Mori Y, Umeda M, Fukunaga M, et al. Contrast in mouse lymph nodes with subcutaneous administration of iron oxide particles; size dependency. Magn Reson Med Sci. 2011;10:219-227.
23. Lei J, Xue HD, Li Z, et al. Possible pathological basis for false diagnoses of lymph nodes by USPIO-enhanced MRI in rabbits. J Magn Reson Imaging. 2010;31:1428-1434.
24. Tanoura T, Bernas M, Darkazanli A, et al. MR lymphography with iron oxide compound AMI-227: studies in ferrets with filariasis. AJR Am J Roentgenol. 1992;159:875-881.
25. Choi SH, Kim KH, Moon WK, et al. Comparison of lymph node metastases assessment with the use of USPIO-enhanced MR imaging at 1.5 T versus 3.0 T in a rabbit model. J Magn Reson Imaging. 2010;31:134-141.
26. Padhani AR. Diffusion magnetic resonance imaging in cancer patient management. Semin Radiat Oncol. 2011;21:119-140.
27. Liu Y, Liu H, Bai X, et al. Differentiation of metastatic from non-metastatic lymph nodes in patients with uterine cervical cancer using diffusion-weighted imaging. Gynecol Oncol. 2011;122:19-24.
28. Thoeny HC, Triantafyllou M, Birkhaeuser FD, et al. Combined ultrasmall superparamagnetic particles of iron oxideYenhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol. 2009;55:761-769.
29. Herborn CU, Vogt FM, Lauenstein TC, et al. Assessment of normal, inflammatory, and tumor-bearing lymph nodes with contrast-enhanced interstitial magnetic resonance lymphography: preliminary results in rabbits. J Magn Reson Imaging. 2003;18:328-335.
30. Saokar A, Braschi M,Harisinghani M.Lymphotrophic nanoparticle enhancedMR imaging (LNMRI) for lymph node imaging. Abdom Imaging. 2006;31:660-667.